SGI-110 and Donor Lymphocyte Infusions (DLI) After Allogeneic Stem Cell Transplantation
Status:
Not yet recruiting
Trial end date:
2022-03-01
Target enrollment:
Participant gender:
Summary
High risk MDS (Myelodysplastic Syndrome) patients will be treated with SGI-110 after
Allogeneic Stem Cell Transplantation in the hypothesis that SGI-110 maintenance given early
after HSCT can prevent relapse without increasing non-relapse mortality translating in an
improved disease-free survival.